Scott Dove, Ph.D.

Scott Dove, Ph.D., is an experienced biopharmaceutical executive with more than 20 years of leadership experience in small and large pharma and the CRO industry. Dr. Dove combines a technical background in clinical development and operations with strong general management capabilities in building and leading strong organizations. Dr. Dove’s drug development experience includes managing multi-disciplinary development teams from manufacturing to marketing authorization, extensively interacting and negotiating with global health authorities, and supporting go-to-market strategies.

Dr. Dove previously served as Senior Vice President and General Manager at PPD, where he provided strategic direction and oversight of PPD’s Early Development Services business unit. In this role, Dr. Dove was responsible for the organizational design and executive management of early phase CRO operations. Prior to joining PPD, Dr. Dove was an Executive Director of Clinical Development with Allergan, serving as global clinical development leader for Viberzi®/Truberzi® (eluxadoline). At Allergan, Dr. Dove negotiated marketing approvals, labeling, and post-marketing requirements for eluxadoline as a treatment for irritable bowel syndrome, while overseeing the development and operational execution of its label expansion and life-cycle management clinical strategy. Dr. Dove previously oversaw the development of eluxadoline as program leader at Furiex Pharmaceuticals, Inc, managing the program through successful NDA submission until the acquisition of Furiex by Actavis plc (now Allergan).

Dr. Dove’s key areas of expertise include early drug development and clinical pharmacology, with extensive therapeutic experience in gastroenterology, endocrinology, dermatology, and immunology. Dr. Dove earned a bachelor’s degree in biochemistry and a doctorate in pharmacology from Texas A&M University.